In a pretty richly valued med-tech space, it takes some setbacks to uncover value and opportunity. Medtronic (NYSE: MDT )
has certainly seen setbacks, as the company has abandoned renal
denervation, has lost some momentum in CRM, and may not be as
competitive as hoped in drug-coated balloons. On a more positive note,
transcatheter heart valves look like a viable growth driver and
Medtronic has several opportunities in areas like neuromodulation,
diabetes, and atrial fibrillation.
Read the full article here:
Multiple Setbacks May Spell Opportunity at Medtronic, Inc.
No comments:
Post a Comment